← All trials
NCT04519073
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2020
- Primary completion
- Mar 1, 2022
- Completion date
- Jun 30, 2022
- First posted
- Aug 19, 2020
- Last posted
- Sep 9, 2020
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- VirometixLead sponsor
- VirometixStudy director
- Ghent UniversityCollaborator
- Expert Clinical Services OrganizationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.